EDGAR·FLOW

Tenon Medical, Inc. — Form 10-Q

Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 72/100
What the filing says
Tenon Medical hired Thomas Batton Jr. as Chief Revenue Officer effective October 1, 2026, with base compensation of $12,500/month plus up to $12,500/month in commissions (25% of first $50K monthly revenue from new physician relationships) and quarterly revenue incentives up to $60K. Concurrently, Nate Grawey was promoted from Chief Commercial Officer to newly-created Chief Strategy and Business Development Officer, with removed day-to-day commercial and field sales responsibilities.
Why this rating

CRO hire with material comp (~$300K annualized base + upside) is significant for $7.3M-market-cap company—represents ~4% of market value in annual salary alone. Organizational restructuring (CCO→strategy role) signals operational shift. Neither clearly positive nor negative without revenue context.

Price action (we called it neutral)
at our read · unknown
$0.00
+10 min · unknown
$0.00 ▲ 0.00%
+30 min · unknown
$0.00 ▲ 0.00%
+1 hr · unknown
$0.00 ▲ 0.00%
+4 hrs · unknown
$0.00 ▼ 8.16%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ TNONW · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.